FAQ: Quantum BioPharma Ltd. Advances MS Drug Toward Phase 2 Trial

What is Quantum BioPharma Ltd. working on?

Quantum BioPharma Ltd. is focusing on developing Lucid-21-302 (Lucid-MS), a patented neuroprotective therapy for multiple sclerosis, and has signed an agreement to prepare an IND application for a Phase 2 clinical trial.

Why is the agreement with a global pharmaceutical contract research organization significant?

This agreement is a crucial step towards submitting an IND application to the FDA by Q4 2025, which is necessary to initiate a Phase 2 clinical trial for Lucid-21-302, potentially advancing treatment for MS.

What is Lucid-21-302?

Lucid-21-302 is a patented, non-immunomodulatory neuroprotective therapy shown in preclinical studies to prevent demyelination, addressing a key mechanism of multiple sclerosis and other neurodegenerative disorders.

When is the IND submission to the FDA planned?

The IND submission to the FDA is planned for the fourth quarter of 2025.

What does Quantum BioPharma Ltd. specialize in?

Quantum BioPharma specializes in developing treatments for neurodegenerative and metabolic disorders, including its lead compound Lucid-MS for multiple sclerosis, and has investments in other biotech solutions.

How can I learn more about Quantum BioPharma Ltd.?

For more information, visit Quantum BioPharma’s newsroom at https://ibn.fm/QNTM or the full press release at https://ibn.fm/E5Lau.

What other projects does Quantum BioPharma Ltd. have?

Beyond Lucid-MS, Quantum BioPharma has developed UNBUZZD, an OTC product for alcohol misuse, and maintains strategic investments through its subsidiary, FSD Strategic Investments Inc.

What are the terms of the agreement with Celly Nutrition Corp.?

Quantum BioPharma retains 25.71% ownership in Celly Nutrition, receives 7% royalties from UNBUZZD sales up to $250 million, then 3% thereafter, and keeps rights to develop similar pharmaceutical products.